Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aslan-003. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 18/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aslan-003 SCHEMBL29409728 | 1.00 | DHODH (1.00) | DHODHHTTMEN1PKMMAPK1 | |
| Aslan-003 SCHEMBL29364008 | 1.00 | DHODH (1.00) | DHODHHTTMEN1PKMMAPK1 | |
| Aslan-003 SCHEMBL3884279 | 0.94 | DHODH (0.92) | DHODHHTTMEN1PKMMAPK1 | |
| Aslan-003 SCHEMBL16742036 | 0.92 | DHODH (0.84) | DHODHHTTMEN1PKMMAPK1 | |
| SCHEMBL356005 | 0.89 | DHODH (1.00) | DHODH | |
| SCHEMBL290518 | 0.88 | DHODH (0.81) | DHODHHTTMEN1PKMMAPK1 | |
| SCHEMBL12082535 | 0.88 | DHODH (0.78) | DHODHHTTMEN1PKMMAPK1 | |
| SCHEMBL729195 | 0.88 | DHODH (0.78) | DHODHHTTMEN1PKMMAPK1 | |
| SCHEMBL2713067 | 0.87 | DHODH (0.77) | DHODHHTTMEN1PKMMAPK1 | |
| SCHEMBL728033 | 0.87 | DHODH (0.77) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145570-A1 | DHODH INHIBITOR POLYMORPH | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2025-05-08 | — | — | US | claimed |
| EP-4362968-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-05-08 | — | — | EP | claimed |
| US-20230390276-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH A DIHYDROOROTATE HEHYDROGENASE (DHODH) INHIBITOR | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2023-12-07 | — | — | US | claimed |
| US-20230355602-A1 | TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2023-11-09 | — | — | US | claimed |
| US-20230338356-A1 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2023-10-26 | — | — | US | claimed |
| WO-2023204754-A1 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2023-10-26 | — | — | WO | claimed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | claimed |
| EP-4228640-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH A DIHYDROOROTATE HEHYDROGENASE (DHODH) INHIBITOR | ASLAN Pharmaceuticals Pte Ltd (SG) | 2023-08-23 | — | — | EP | claimed |
| WO-2023149841-A1 | DHODH INHIBITOR POLYMORPH | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2023-08-10 | — | — | WO | claimed |
| EP-4203953-A1 | TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION | ASLAN Pharmaceuticals Pte Ltd (SG) | 2023-07-05 | — | — | EP | claimed |
| JP-2011524392-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110129445-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-02 | — | — | US | claimed |
| EP-2314577-A1 | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid | Almirall, S.A. (ES) | 2011-04-27 | — | — | EP | claimed |
| WO-2011045059-A1 | PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4-YL)AMINO]NICOTINIC ACID | ALMIRALL, S.A. (ES) | 2011-04-21 | — | — | WO | claimed |
| EP-2296663-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | Almirall, S.A. (ES) | 2011-03-23 | — | — | EP | claimed |
| WO-2010102826-A1 | ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | WO | claimed |
| EP-2228367-A1 | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| WO-2009153043-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-12-23 | — | — | WO | claimed |
| EP-2135610-A1 | Combination comprising DHODH inhibitors and methotrexate | Laboratorios Almirall, S.A. (ES) | 2009-12-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338356-A1 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | DHODH, DHCR7, ASAH2 | DHODH 1/4885HTT 2953/4885MEN1 3179/4885 |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885HTT 770/4885MEN1 2373/4885 |
| US-20230390276-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH A DIHYDROOROTATE HEHYDROGENASE (DHODH) INHIBITOR | DHODH, HAAO, FH | DHODH 1/4885HTT 481/4885MEN1 1319/4885 |
| US-20100074898-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, NQO2, DAO | DHODH 1/4885HTT 941/4885MEN1 4210/4885 |
| US-20250145570-A1 | DHODH INHIBITOR POLYMORPH | DHODH, DHX15, DPYD | DHODH 1/4885HTT 1140/4885MEN1 4122/4885 |
| US-20110129445-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | DHODH, DHFR, MTHFD2 | DHODH 1/4885HTT 2121/4885MEN1 3384/4885 |
| US-20230355602-A1 | TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION | DHODH, HAVCR2, DOHH | DHODH 1/4885HTT 3070/4885MEN1 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.